Research has shown that another proteīns called tau is responsible for early symptoms of Alcheimera slimība un šī informācija var palīdzēt izstrādāt terapiju.
Alcheimera Disease (AD) or simply Alcheimera has no cure and it also cannot be prevented. Deferring the onset of symptoms of Alcheimera for up to 10-15 years can certainly impact the lives of pacientes, their families and healthcare givers. Currently, only a late diagnosis of AD can be made and by that time function of the brain is largely weakened. Key characteristics of Alcheimera is build-up of plaque and defective proteīni around neurons inside the brain which are responsible for advancement of the slimība. Multiple research shows that higher levels of proteīns amyloid in the smadzenes ir ļoti agrīni AD attīstības rādītāji. Lielākā daļa pētījumu par Alcheimera slimība ir koncentrējies uz izpratni par to, kā tas notiek proteīns amyloid beta accumulates in the brain. Positron Emission Tomography (PET) imaging technique has been used to visualize deposits of amyloid in Alzheimer’s patients. These images and analysis of brain tissue has shown that people with Alzheimer’s definitely have higher accumulation of amyloid proteīns in their brains compared to healthy people.
Is there another proteīns responsible?
Though it is seen that even after amyloid beta gets accumulated and Alzheimer’s disease is at its earliest stage, many patients still have their cognitive processes – both memory and thought – very much intact. This is indicative of a scenario in which amyloid proteīns must be changing first and then there must be some other factor responsible which researchers predicted could be a second proteīns present inside brain cells called tau. It could even be a combination of both because of which a patient may show mild cognitive impairment. Interestingly, even people who have no signs of Alzheimer’s have sometimes amyloid proteīni accumulated in their brains. Recent studies have generated interest in tau proteīns which though has been associated with the disease but hasn’t been the focus of much research. One obstacle in pursuing study on tau proteīns has been that a non-invasive way to get an image of this protein inside a living person’s brain has been only lately achieved. Researchers at Washington University School of Medicine, St. Louis have used a previously unknown imaging agent which binds to the tau protein (without causing side effects) making it visible in PET scans. In their study they aimed to understand the significance of tau as a marker of cognitive decline – a critical characteristic of Alcheimera. Their study is published in Science Tulkošanas medicīna.
In the study, 46 participants – 36 healthy adults and 10 patients with mild AD – underwent brain imaging which used the new PET imaging agent. Their brain images were then compared to understand decline in cognitive abilities due to AD. The extent of cognitive impairment was evaluated using cerebrospinal fluid measures, clinical dementia rating and paper tests for memory and other brain functions. The severity of cognitive dysfunction was analysed along with images. Results seen in 10 patients (with mild AD) in PET scans clearly showed that tau is a better predictor of symptoms of cognitive decline compared to amyloid. And tau protein might be more closely linked to symptoms like memory loss. This new tau protein (called T807) is seen to be critical in firstly understanding progression of Alcheimera and secondly to gather information about which portions of the brain are affected and involved in disease progression. Though increased tau protein is already an established marker of Alcheimera but for the first-time regions in the brain which accumulate these abnormal proteins have been pinpointed. As long as tau is deposited in the hippocampus of the brain, its well tolerated. Its spread to other areas like temporal lobe (which is associated with memory processing) can be damaging which is reflected in memory and attention tests. This allows potential use of tau as a diagnostic tool. Such a situation was not applicable to amyloid protein and this confirmed that tau protein can predict more accurately when a person is transitioning from an early stage – with no symptoms – to mild Alcheimera disease. A combination of both amyloid and tau could also be responsible. The study does have some limitations because the images are basically ‘one snapshot’ of the brain at one point of time and they cannot wholly depict association of tau and mental deterioration.
Tā kā attēlveidošanas līdzekļi tagad ir pieejami gan amiloīda beta, gan tau, diskusijas par to, kura ir svarīgāka, var turpināties, taču var izmantot nepieciešamos rīkus, lai pētītu eksperimentālo terapiju ietekmi, kas vērsta uz abiem šiem proteīniem. Jaunais tau attēlveidošanas līdzeklis jau ir apstiprināts klīniskajiem pētījumiem, un to var izmantot smadzeņu attēlveidošanā dažādiem traucējumiem, kas saistīti ar paaugstinātu tau proteīna līmeni, piemēram, smadzeņu traumu vai traumu gadījumā. Pastāv milzīga cerība, ka agrāka Alcheimera slimības diagnoze varētu palīdzēt izstrādāt zāles amiloīda un tau proteīnu uzkrāšanai. Pētnieki optimistiski ierosina personalizētu Alcheimera terapiju nākotnē, kuras pamatā būtu precīzs scenārijs pacienta smadzenēs.
***
{Jūs varat izlasīt oriģinālo pētījumu, noklikšķinot uz DOI saites, kas norādīta tālāk citēto avotu sarakstā}
Avots (-i)
Brier MR 2018. Tau un Ab attēlveidošana, CSF pasākumi un izziņa Alcheimera slimībā. Zinātnes atklājumu Medicīna. 8 (338). https://doi.org/10.1126/scitranslmed.aaf2362
***
